
Our Mission
VerAvanti was founded to address a fundamental limitation in endoscopic imaging. Many of today’s devices were designed decades ago, relying on side-view visualization and reusable systems that can limit workflow efficiency and introduce operational challenges in modern clinical environments.
In collaboration with the University of Washington, VerAvanti developed the patented Scanning Fiber Endoscope (SFE), a new approach to endoscopic imaging designed to deliver high-quality visualization through ultra-small, single-use devices.
Our focus is to enable physicians to see more clearly, work more efficiently, and make better-informed decisions during minimally invasive procedures. By combining precision engineering with a commitment to patient safety and clinical practicality, VerAvanti is building imaging technologies designed for the needs of modern healthcare.
VerAvanti is currently pursuing 510(k) clearance by the U.S. Food and Drug Administration (FDA) and preparing to expand production and introduce our diagnostic solutions worldwide. Committed to ongoing innovation, we aim to improve healthcare standards by making procedures safer, faster, and more effective for both patients and providers.
The Timeline


1
Foundational Research and Collaboration
Laying the groundwork for groundbreaking technology.
Initial research began in collaboration with the University of Washington, forming the basis for our fiber-optic endoscopy innovations.
%20(1).webp)

2
Prototype Testing and Validation
Ensuring safety and effectiveness through testing.
Early prototypes underwent rigorous lab and clinical testing, validating our imaging excellence.


3
Securing 50+ Patents
Protecting our technology through comprehensive patents.
We secured over 50 patents in the U.S.A, reinforcing VerAvanti’s commitment to advancing exclusive, protected innovations.
.jpg)

5
Final Production Model Established
Refining the design for scalability and precision.
The production model is under finalization, with in-house manufacturing processes set up to maintain quality and precision at scale.


6
FDA Approval and Market Launch
Bringing VerAvanti’s innovations to healthcare providers.
With FDA approval anticipated by Q1 2026, VerAvanti is poised to launch its technology globally, redefining standards in diagnostics and treatment.
Leadership

Gerald McMorrow
Founder and CEO

Luis Savastano
Chief Medical Officer

Juan Vegarra
Chief Revenue Officer

Jason Capodanno
Chief Operating Officer
Clinical Advisors

Patrick McVeigh, MD
MD

Mark Reisman
Clinical Professor of Medicine

William Lombardi
Associate Clinical Professor of Medicine

John Petersen
Director of Cardiovascular Research

Gerald McMorrow
Chairman of the Board

Fred Moll
M.D., Founder and CEO of Auris Health

David C. Auth
Ph.D, Affiliate Professor of Bioengineering

Michael Moyer
Board Member



